CONSULTATION

PHARMAC
Pharmaceutical Management Agency

5 September 2014

Proposal to list ceftaroline fosamil in Section H of the Pharmaceutical Schedule

PHARMAC is seeking feedback on a proposal to list ceftaroline fosamil in Part II of Section H of the Pharmaceutical Schedule, through a provisional agreement with AstraZeneca Limited.

In summary, this proposal is to list ceftaroline fosamil for use in DHB hospitals for multi-resistant organism salvage therapy from 1 November 2014.

Full information on the proposal can be found below.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 19 September 2014** to:

Greg Williams
Senior Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: greg.williams@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or its delegate acting under delegated authority) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Details of the proposal

Ceftaroline fosamil would be listed in Part II of Section H of the Pharmaceutical Schedule at the following price from 1 November 2014 (ex-manufacturer, excluding GST):

Chemical	Presentation	Brand	Pack size	Price
Ceftaroline fosamil	Inj 600 mg vial	Zinforo	10	$1,450.00

Ceftaroline fosamil would be listed subject to the following restriction in Part II of Section H of the Pharmaceutical Schedule:

Ceftaroline fosamil
Restricted
Infectious Disease Physician or Clinical Microbiologist
Multi-resistant organism salvage therapy
Either**:**
1. for patients where alternative therapies have failed; or
2. for patients who have a contraindication or hypersensitivity to standard current therapies.

Background

PTAC and the Anti-Infective Subcommittee of PTAC considered ceftaroline fosamil at their meetings of 8 & 9 May 2014 and 26 February 2014 respectively. The relevant minutes can be found at the following links:

http://www.pharmac.health.nz/assets/ptac-minutes-2014-05.pdf
http://www.pharmac.health.nz/assets/ptac-anti-infective-subcommittee-minutes-2014-02.pdf

PTAC recommended funding ceftaroline as a last line agent in the treatment of multi-resistant infections with a high priority. The Committee considered that there was not likely to be significant usage of ceftaroline until the evidence for use in multi-resistant organisms was more robust.

The proposed restriction is in line with PTAC's recommendation, which was intended to ensure effective antimicrobial stewardship. This is not a registered indication for ceftaroline